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IntroductionCoronary artery disease (CAD) is the leading cause of death worldwide [1,2]. Atherosclerosis of the coronary arteries is the 
underlying pathogenic mechanism and is driven by inflammation within the arterial intima in response to stressors including 
oxidised LDL cholesterol (ox-LDL) [3,4]. IL-1β is a major molecular determinant of atherosclerosis and is activated within the NLRP3 
inflammasome. Atheromatous plaque build-up; acute plaque rupture and arterial thrombosis result in myocardial ischaemia and acute myocardial infarctions (AMI) respectively [5]. The mainstays of current treatment are medical or surgical. Medical interventions 
include statins to lower LDL; anti-coagulation; anti-hypertensives 
and cardiac contractility modifiers to reduce strain on ischaemic, post-infarction and pathologically remodelled hearts. Surgical interventions (PCI: Percutaneous Coronary Intervention and CABG: 
 Coronary Artery Bypass Graft) aim to revascularize ischaemic myocardial tissue [6]. However, there exists a clinical need for more effective targeted therapies to curtail disease progression 
and prevent recurrent events. Targeted anti-inflammatory agents 
are gaining traction in many diseases with an inflammatory basis, 
including in CAD, where IL-1β and/or NLRP3 inhibitors represent promising candidates [5,7].
IL-1β role in CAD
IL-1β is a key cytokine mediator of the response to infection 
and inflammation [8]. It plays an important role during all stages of atherosclerosis and CAD development, acting both within the vasculature wall and systemically [9]. Levels have been shown to 
correlate with atherosclerosis progression [10]. IL-1β modifies cholesterol metabolism [11], augmenting ox-LDL synthesis and 
Abstract
Coronary Artery Disease (CAD) represents a major health burden worldwide. It is driven by chronic inflammation of the arterial vasculature 
supplying the heart, in response to pro-inflammatory assaults such as high LDL cholesterol. The resultant atherosclerosis can cause occlusive 
disease and acute cardiovascular events. The pro-inflammatory cytokine, IL-1β is a central component of this inflammatory response and 
signalling is activated and amplified by the NLRP3 inflammasome. Rational therapeutic targeting of these mediators could modify atherosclerotic 
disease progression; myocardial remodelling and CAD patient outcomes. Here we discuss promising current and pipeline inhibitors of the NLRP3 
inflammasome family. 
Keywords: Coronary artery disease; Atherosclerosis; IL-1β; NLRP3 inflammasome; IL-1β inhibitors; NLRP3 inhibitors
Abbreviations: CAD: Coronary Artery Disease; PCI: Percutaneous Coronary Intervention; CABG: Coronary Artery Bypass Graft; PAMPS: Pathogen-
Associated Molecular Pattern Molecules; DAMPS: Damage-Associated Molecular Patterns; NLRP3 (NOD [Nucleotide Oligomerization Domain]-, LRR 
[Leucine-Rich Repeat]-, And PYD [Pyrin Domain]-Containing Protein 3); ASC: Apoptosis-Associated Speck-Like Protein Containing A CARD; NLRC4: 
NLR Family CARD Domain Containing 4; AMI: Acute Myocardial Infarction.
Online Journal of Cardiovascular Research                                                                                                                         Volume 3-Issue 2
Citation: Victoria McGilligan, Shauna Donnelly, Roisin McAllister, Melody  Chemaly, Tony Bjourson, Aaaron Peace. The NLRP3 Inflammasome as a promising target for Coronary Artery Disease: Current and Pipeline NLRP3 Inhibitors. On J Cardiovas Res. 3(2): 2019. OJCR.MS.ID.000556. DOI: 10.33552/OJCR.2019.03.000556. Page 2 of 7
promotes immune cell extravasation into the arterial intima 
during early plaque formation. Phagocytosis of ox-LDL by recruited 
macrophages forms engorged “foam cells” that secrete IL-1β. Vascular smooth muscle cell proliferation is promoted, along with IL-6 expression from multiple cell types. Increased vascular 
inflammation contributes to plaque fibrosis; destabilisation and the 
rupture of vulnerable atherosclerotic plaques [4,5]. The acute phase response is induced (along with CRP) and the blood coagulation cascade is triggered, precipitating acute cardiovascular events 
[12]. IL-1β further plays a role in the pathological remodelling of 
the myocardium [13]. Subsequent to ischaemia-reperfusion, acute 
and chronic phases of inflammation and IL-1β expression drive 
the fibrosis and cell death known to permanently damage the myocardial tissue and cause heart failure [14]. 
NLRP3 Inflammasome in CAD
Inflammasomes are cytoplasmic oligomeric signalling 
complexes, formed within inflammatory cells, cardiomyocytes and endothelial cells in response to invading pathogens (PAMPs: Pathogen-Associated Molecular Patterns) and endogenous danger signals such as ox-LDL and cholesterol crystals (DAMPs: Damage-Associated Molecular Patterns). The NLRP3 (NOD [nucleotide oligomerization domain]-, LRR [leucine-rich repeat]-, and PYD 
[pyrin domain]-containing protein 3) inflammasome is the best 
characterised, and comprises NLRP3 (the sensing receptor); ASC 
(the adaptor) and caspase-1 (the effector that cleaves IL-1β and 
IL-18 pro-polypeptides) amplifying the inflammatory response 
[15,16]. NLRP3 inflammasome activation is rate limited by the basally low levels of NLRP3 mRNA maintained within cells [17]. Activation proceeds in a two-step manner. Firstly, a priming step 
induces NF-ƘB-mediated transcription of the NLRP3 and IL1B genes. Various lipid agonists, including LPS (lipopolysaccharide) and FFAs (free fatty acids) bind to TLRs and signal through the 
adaptor Myd88 and ox-LDL can induce signal one through a CD36/
TLR4/6 complex. TNFα/TNFR binding can further induce NF-ƘB 
activation. The second signal is required for NLRP3 component assembly and can be derived from intracellular molecules including ROS (reactive oxygen species) and cholesterol derivatives, degraded 
within the lysosome [16,18]. Assembly is further dependent on ATP, released from necrotic cells, binding the P2X7R and inducing K+ 
ion efflux. Recruitment of ASC (apoptosis-associated speck-like protein containing a CARD) facilitates pro-caspase-1 proximity 
induced activation to caspase-1 and cleavage of pro- IL-1β and pro-
IL-18 [19]. These cytokines then activate other immune cells to 
propagate the immune response. IL-1β binding to its cognate IL1R 
provides a feed-forward amplification loop. Pyroptopsis is a form of cell death activated by ischaemia and mitochondrial damage during AMI [20]. It releases intracellular molecules (such as ATP) 
further promoting NLRP3 activation. Consequently, a cycle of NLRP3 activation within the atheroma leads to chronic low-grade 
inflammation and advanced plaque formation and atherosclerotic 
plaques are associated with high levels of NLRP3 mRNA expression [21] (Figure 1).
Figure 1: NLRP3 inflammasome two-step activation: The first priming step is initiated by lipid and lipoprotein endogenous danger signals and 
pathogen associated molecules (FFA: free fatty acids; ox-LDL: oxidised low density lipoprotein; cholesterol crystals; LPS: lipopolysaccharide) 
and cytokines (IL-1β and TNFα) that signal through MyD88 to activate NF-ƘB mediated upregulation of NLRP3 and IL1B mRNA. The second 
signal is provided by diverse intracellular and extracellular molecules (ROS: reactive oxygen species released from mitochondria; lysosomally 
degraded ox-LDL and cholesterol crystals) and extracellular ATP binding to the K+ channel P2X7R. This initiates NLRP3 inflammasome 
component (NLRP3; ASC; Pro-caspase-1) assembly and activation of caspase-1 to cleave the pro-peptides and release IL-1β and IL-18. 
These mediators then prime other immune cells. Intracellular molecules are also released by pyroptopsis.
Citation: Victoria McGilligan, Shauna Donnelly, Roisin McAllister, Melody  Chemaly, Tony Bjourson, Aaaron Peace. The NLRP3 Inflammasome as a promising target for Coronary Artery Disease: Current and Pipeline NLRP3 Inhibitors. On J Cardiovas Res. 3(2): 2019. OJCR.MS.ID.000556. DOI: 10.33552/OJCR.2019.03.000556.
Online Journal of Cardiovascular Research                                                                                                                         Volume 3-Issue 2
Page 3 of 7
Inhibitors of the IL-1β Pathway 
Due to its central role in atherosclerosis, targeting the IL-1β pathway is a plausible approach for CAD therapeutic management. 
Many IL-1β inhibitors have been investigated in recent years in 
many diseases that have an underlying inflammatory component 
[22]. Anakinra is a recombinant human IL-1 competitive receptor antagonist FDA approved for rheumatoid arthritis treatment. Its utility is, however, reduced by its biological half-life (4hrs) 
[23,24]. Canakinumab is a recombinant human monoclonal 
antibody that selectively inhibits IL-1β receptor binding [25]. The CANTOS clinical trial supported the role of atherosclerosis in 
CAD and served as a proof of concept that an IL-1β inhibitor could 
influence the trajectory of atherosclerosis development without 
plasma cholesterol reduction [26,27]. The use of canakinumab is 
restricted nevertheless as it can cause fatal opportunistic infections 
and sepsis [28]. Gevokizumab showed better tolerance in Phase II clinical trials [29]. Rilonacept is a soluble decoy receptor antagonist 
of IL-1 that binds with a high affinity to IL-1β and blocks its activity; 
but has also displayed adverse reactions including injection site 
reactions and infections [30]. Therefore, targeting inflammatory 
signalling at the level of IL-1β may not be the optimal level for 
pathway attenuation in atherosclerosis [31,32]. IL-1β is processed 
by multiple types of inflammasomes (including NLRC4), especially in response to pathogenic assaults [33]. Targeting upstream of 
IL-β by specifically targeting NLRP3 the main orchestrator of IL-1ß activation presents an attractive option, thereby leaving other 
methods of IL-1β production to respond to severe infection if 
required (Table 1).
Table 1: Summary of IL-1β inhibitors.
IL-1β inhibitor Mode of inhibition Tested in context of CAD CAD Clinical trial References
Anakinra
Recombinant human IL-1 competitive receptor antagonist Yes Yes (Phase II – no results posted) [24,69]
Canakinumab Selectively inhibits IL-1β receptor binding Yes Yes (Phase III – no results posted) [26,70]
Rilonacept Decoy receptor antagonist of IL-1 that binds with a high affinity to IL-1β and blocks its activity Yes Yes (Phase II – results posted) [31,71]
Gevokizumab
Decreases the binding affinity of IL-1β for the IL-1 receptor type I (IL-1RI) signalling receptor Yes No [72]
Inhibitors of the NLRP3 Inflammasome
The NLRP3 inflammasome amplifies the local inflammatory response within the arterial intima and myocardium, in a feed-
forward signalling loop to produce IL-1β. Therefore, inhibition 
of this inflammasome might quell IL-1β inflammatory signalling; 
without complete IL-1β pathway blockade and accompanying susceptibility to infection. Further, NLRP3 targeting is potentially 
more specific than inhibiting IL-1β, where inhibitor off-target 
binding to IL-1α can further dampen the immune response to pathogens. 
Non-specific Inflammasome Inhibitors 
Several known drugs have non-specific NLRP3 inflammasome 
inhibition properties. Arglabin is a sesquiterpene lactone antitumor agent isolated from Artemisia species [34]. Pre-clinical studies demonstrated NLRP3 inhibition in macrophages that were exposed to cholesterol crystals and attenuation of atherosclerotic 
progression in ApoE2.ki mice on a high fat diet [35]. Difficulties in large-scale production of this agent would hinder its clinical use [36]. Atorvastatin, the most commonly used cholesterol reduction therapy, is a 3-hydroxyl-3-methylglutaryl coenzyme A inhibitor that 
has anti-inflammatory properties [37]. It inhibits NLRP3 activation 
via TLR4/MyD88/NF-ƘB signalling in PMA-stimulated THP-1 
monocytes and halts atherosclerotic plaque progression in patients 
receiving high-dose atorvastatin [38]. Other statin analogues display similar properties [39]. Studies have shown mild adverse events associated with atorvastatin such as mild gastrointestinal complaints and central nervous effects, mainly headaches [40]. Colchicine derived from Colchicum autumnale is used for the 
treatment of gout [41]. Recent studies have shown it is capable 
of inhibiting NLRP3 inflammasome activation by interfering with its oligomerisation [42]. In clinical trials it reduced CRP levels in patients with stable CAD and it may possess a protective effect in stable CAD [43]. However, it is prone to drug-drug interactions and off-target effects, reducing its clinical potential [44]. Glyburide is a sulfonylurea-based compound used to treat type 2 diabetes. In diabetes it inhibits ATP-dependent K+ channels to augment 
insulin secretion [45]. Its inhibition of the NLRP3 inflammasome however is independent of K+ channel activation and its molecular 
target is unknown. A further drawback is that this inhibitor has a relatively high IC50 value (100μM in trophoblasts) increasing the chance of off-target effects [46]. Natural metabolites produced by 
the body can also inhibit the NLRP3 inflammasome. The ketone 
body β-hydroxybutyrate (BHB) is an alternative source of ATP in 
mammals during states of energy deficit. BHB can reduce NLRP3 
inflammasome-mediated interleukin IL-1β and IL-18 production 
in human monocytes. In mice BHB or a ketogenic diet attenuates 
caspase-1 activation and IL-1β secretion, demonstrating its potential to curtail NLRP3-mediated diseases [47].
Specific and Pipeline Inflammasome Inhibitors
Specific, small molecule NLRP3 inhibitors have generally been 
identified through phenotypic screening for bioactivities. However, 
due to the complexity of the NLRP3 activation pathway; inhibition may be direct or via accessory proteins and the mechanistic basis of their activity is mostly elusive. CP-456,773 (MCC950) is the best characterised NLRP3 inhibitor. It is another sulfonylurea-
containing compound and small molecule that is a highly specific 
Online Journal of Cardiovascular Research                                                                                                                         Volume 3-Issue 2
Citation: Victoria McGilligan, Shauna Donnelly, Roisin McAllister, Melody  Chemaly, Tony Bjourson, Aaaron Peace. The NLRP3 Inflammasome as a promising target for Coronary Artery Disease: Current and Pipeline NLRP3 Inhibitors. On J Cardiovas Res. 3(2): 2019. OJCR.MS.ID.000556. DOI: 10.33552/OJCR.2019.03.000556. Page 4 of 7
NLRP3 inflammasome inhibitor, that inhibits NLRP3 ATPase 
activity and attenuates IL-1β secretion by all known activators 
(including ATP) [48]. Apolipoprotein E-deficient mice treated 
with MCC950, showed a reduction in atherosclerotic plaques by 
reduction in plaque monocyte adhesion molecules [49]. Clinical use will, however, be limited by the molecule’s short half-life (3.27hrs) 
and the associated drawbacks of daily injections and site reactions 
[50]. OLT1177, a β-sulfonyl nitrile compound has been shown to be safe in humans and is another selective NLRP3 inhibitor [51]. Very recently it was reported that OLT1177 (dapansutrile) limits infarct size and prevents left ventricular systolic dysfunction when 
given within 60 minutes following ischemia reperfusion injury in the mouse [52]. 16673-34-0 is a small molecule inhibitor and an intermediate substrate in glyburide synthesis. It inhibits the 
formation of the NLRP3 inflammasome in cardiomyocytes and limits the infarct size after myocardial ischemia–reperfusion in a mouse model [53]. Tranilast is an old anti-allergic drug, recently 
been shown to be a specific NLRP3 inflammasome inhibitor by preventing its oligomerisation [54] and was have shown Tranilast 
to reduce atherosclerotic plaque development [55]. Further novel 
agents are being developed; although not yet tested in CAD. CY-
09 was identified through structure–activity relationship studies and was shown to inhibit NLRP3 ATPase activity. In mice fed a 
high fat diet, CY-09 reduced blood glucose and insulin levels [56]. Other potent NLRP3 inhibitors such as NT-0167 (NodThera™) 
are being trialled in fibrosis [57]. Inflammasome Therapeutics 
Inc™. have identified kamuvudines that are chemical derivatives of Nucleoside Reverse Transcriptase Inhibitors (NRTIs), the mainstay of HIV treatment regimens. These agents inhibit P2X7R-
mediated NLRP3 inflammasome activation independent of targeting reverse transcriptase. They are currently being tested in 
macular degeneration and type 2 diabetes [58,59]. Other agents 
can target the NLRP3 inflammasome at the level of ASC. IC100 is a monoclonal antibody developed by Zyversa Therapeutics™ that 
inhibits the adaptor ASC component of multiple inflammasomes, 
offering the potential to treat a broad group of inflammatory disorders, notably multiple sclerosis [60]. However, since ASC is 
common to many inflammasome species, the risk of non-specificity and infections remains problematic. Nevertheless, the avenue of ASC inhibition warrants exploration in CAD. The development of 
biologic agents (such as IC100) offers the benefits of enhanced 
specificity and longer therapeutic half-lives over the small molecule inhibitors. They can, however, be more expensive to produce and cell penetrability can be an issue [61,62]. There are reports of novel ways being developed to assist entry of antibodies inside the cell [63] (Table 2). 
Table 2: Summary of current and pipeline NLRP3 inhibitors.
NLRP3 inhibitor Mode of Inhibition
Tested in 
context of CAD
CAD Clinical trial References
Atrovastatin Selectively inhibits NLRP3 activation – 
suppresses TLR4/MyD88/NF-κB pathway
Yes Yes (phase IV – no results posted) [37,73]
Colchicine Inhibits NLRP3 by disrupting β-tubulin polymerization into microtubules and inhibits adhesion molecules No Yes (Phase II – no results posted) [43,74]
Arglabin Selectively inhibits NLRP3-induces autophagy and reduces cholesterol levels and 
inflammation
Yes No [36]
MCC950 Interacts with NLRP3 and blocks ATP hydrolysis-inhibits NLRP3 activation and formation Yes No [49]OLT1177 Selective NLRP3 inhibitor, β-Sulfonyl nitrile compound. Yes       Yes (Phase Ib) [51,52] Tranilast Directly binds to NLRP3 and inhibits oligomerization Yes No [55]
BHB Supresses NLRP3 in response to urate crystals, ATP and lipotoxic fatty acids – prevents K+ 
efflux
No No [48]
CY-09 Inhibition of NLRP3 ATPase and oligomerisation No No [57]Glyburide Independent of K+ channel activation. 
Molecular target unknown
No No [46]IC 100 Inhibits ASC component No No [61]NT-0167 A potent selective NLRP3 inhibitor No No [58]16673-34-0 Inhibits NLRP3 formation in cardiomyocytes No No [54]
Kamuvudines Inhibits P2X7R-mediated NLRP3 inflammasome activation No No [57,58]
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Conclusion There exists a salient need for therapeutics capable of modifying CAD progression and for improving clinical outcomes. 
Cholesterol lowering statins are the mainstay of treatment; but 
plaque progression occurs in most patients irrespective of lowered cholesterol levels [63]. The chronic nature of the disease lends itself 
to anti-inflammatory pharmacological management. Targeting 
the inflammation driving atherosclerosis is a rational approach 
with demonstrated success in the seminal CANTOS trial of IL-1β 
inhibitor canakinumab. In a large patient cohort with stable CAD, 
inflammatory markers (including IL-6 and CRP) were lowered 
and the risk of an acute event or a recurrent event was reduced, independent of cholesterol lowering. This provides proof of 
concept that dampening of atherosclerotic chronic inflammation could augment existing statin lowering therapies [39]. However, 
targeting IL-1β directly may be not be the optimal strategy; as it could interfere with systemic immune homeostasis. Susceptibility to infection is a limitation that may reduce the clinical utility of such 
agents [64]. The NLRP3 inflammasome activates and amplifies IL-
1β signalling by integrating multiple pathogen and endogenous danger signals. It is an established mediator of atherosclerotic 
plaque formation and progression and acts locally to activate 
and amplify the inflammatory response. It may therefore be a 
more specific target. Known drugs, including glyburide (an anti-
diabetic agent), have NLRP3 inhibitory properties; although 
predicable off-target effects and lack of efficacy may limit their 
use in CAD. Specific inhibitors are largely being identified through phenotypic screens and often the mechanism of action is unclear 
or unknown; although many specifically target NLRP3 activation at the level of oligomerisation. Testing so far has been pre-clinical. Encouraging results in mouse studies have shown that reduction 
in markers of NLRP3 activation (caspase-1, IL-1β) correlate with 
a reduction in plaque progression. Abderrazak et al. [35] found 
that arglabin could reduce plaque progression in mice genetically engineered to have high blood cholesterol. MCC950 is a potent 
and specific NLRP3 inhibitor with similar properties [49]. If 
initiated early enough; such agents could maintain atherosclerosis at a sub-clinical level. These agents may also have clinical utility in reducing the damage heart muscle sustains post-myocardial infarction. In mice, 16673-34-0 was shown to reduce infarct size after myocardial ischemia–reperfusion [53]. However, caution is 
always required when extrapolating mouse studies into humans [65]. The detailed mechanisms of NLRP3 activation in response to activating signals and its negative regulation are still being fully elucidated [66]. Additionally, no X-ray crystallographic structures have been resolved for the NLRP3 components, limiting rational 
drug design [67]. Filling in these knowledge gaps will facilitate 
the development of more specific agents. Currently, the targeting of other accessory proteins such as ASC is being explored. Still, many of these agents are encumbered with the problem of short 
half-lives and site injection reactions. Improved drug formulations 
and pharmacokinetics will help circumvent the issues. BHB has been shown to reduce NLRP3 activation [47], demonstrating the 
potential for non-pharmacologic interventions. Excessive alcohol 
consumption is a known cardiovascular disease risk factor [68]; that may also inhibit NLRP3 activation [69] Therefore, it is also 
encouraging that lifestyle changes, in the form of ketogenic diets 
and modified ethanol consumption, may provide a drug-free alternative to CAD outcomes [70-75].
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